TY  - JOUR
AU  - Hemminki, Kari
AU  - Zitricky, Frantisek
TI  - Visual presentation of age differences in relative survival of hematological neoplasms in Sweden and the neighboring countries.
JO  - Annals of hematology
VL  - 104
IS  - 3
SN  - 0939-5555
CY  - New York
PB  - Springer
M1  - DKFZ-2025-00501
SP  - 1985-1993
PY  - 2025
N1  - 2025 Mar;104(3):1985-1993 / #EA:C020#EA:Z999
AB  - For many hematological malignancies (HMs) survival among older patients is compromised. We want to test the most up-to-date age-group-specific survival differences in five hematological malignancies, Hodgkin lymphoma (HL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and myeloproliferative diseases (MPD) in Sweden (SE) and compared these to Denmark, Finland and Norway. For analysis we apply a recently published metric for comparing and visualizing age-group-specific relative survival differences using data from the NORDCAN database between 1972 and 2021. Periodic changes in age-related deviation in SE survival showed increasing differences for AML and MM while for the other HMs the differences declined in the course of time. Country-specific differences were observed, for Finnish male CLL and female MPD deviations were larger than those for the other countries, both of which were explained by the deviant survival of the oldest patients. Age-related deviations in 5-year survival increased for AML and MM for which survival improvements have been achieved through intense treatment regimens but these are not offered to old patients because of risk of complications. Paradoxically, improving overall survival in AML and MM has contributed to the widening of the age gaps. For the remaining HMs, age-related deviations declined with time as even old patients benefitted from the survival improvements; most notably female MPD and CLL patients had hardly any age gaps. Age disparities are an issue in hematological malignancies, and an intense search for novel treatments also includes old patients with an example of success as a novel drug venetoclax.
KW  - Cancer registry (Other)
KW  - Periodic survival (Other)
KW  - Prognosis (Other)
KW  - Treatment (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40047911
DO  - DOI:10.1007/s00277-025-06291-4
UR  - https://inrepo02.dkfz.de/record/299557
ER  -